Thursday, September 27, 2012

Mining Stock News: SilverCrest (TSX.V: SVL) Reports High Grade Surface Sampling and Additional Drill Results - 157m @ 94.1 gpt Ag Eq* at La Joya

VANCOUVER, BC - September 27, 2012 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX-V:SVL)(NYSE MKT:SVLC) (the "Company") is pleased to announce the results of an additional 15 holes of the Phase II drill program and additional surface sampling currently underway at its La Joya Property in Durango, Mexico. The Phase II drill program has been expanded by 10 holes to 90 holes totaling 20,000 metres. Phase II drilling reported to date has extended the Main Mineralized Trend ("Trend") beyond the area containing the current Inferred Resource of 101.9 million ounces Ag Eq.*(see News releases dated March 20 and May 7, 2012 and attached figure). Newly constructed drill roads have exposed high grade surface mineralization with Ag Eq values ranging from 72.6 grams to 187.6 grams over sample intervals ranging from 39.7 metres to 99 metres. Drilling and surface sampling has now extended the Trend to approximately 2.5 kilometres with an average width of approximately 700 metres. Please reference our revised website at www.silvercrestmines.com for more information, photos and figures on La Joya.

J. Scott Drever, President stated: "Since announcing the Inferred Resource of more than 100 million ounces Ag Eq. at La Joya, we have completed an additional 64 core holes in the expanded Phase II program of 70 core and 20 RVC holes. The drill results continue to support our large tonnage silver deposit model and the extensive surface sampling in conjunction with certain drill holes support the concept of a potentially higher grade, open pit concept. The remaining drill holes will be directed to establishing additional resources and a basis for a conceptual open pit evaluation."
Drilling and surface sampling confirms the presence of multiple mineralized systems with metal content dependent on proximity to an underlying intensive body which comes to surface in the southwest portion of the Trend. There is distinct zonation of metals both vertically and laterally that has created an Ag, Au, Cu zone along the main portion of the Trend and a near surface tungsten (W), Cu, Au zone on the southwest portion of the Trend. Tungsten mineralization adjacent to the intrusive(s) is found in virtually all the holes drilled to date.
Five of the 15 holes reported in the tables and text below continued to test the southern extension of the Trend and the remaining 10 holes focused on the delineation of the Contact Zone within the Trend and Santo Nino Target. An extensive, channel surface sampling program along new road cuts has been completed within the Trend and subsequent Contact Zone area with 196 recent assay results. Composites of the surface sampling results are presented in the Tables below and attached figure.
Silver values in this series of core holes and surface channel samples along the Trend range from 1.6 gpt to 119.1 gpt and on a silver equivalent* basis values range from 11.0 gpt to 200.3 gpt Ag Eq. Mineralized intervals range from 8.9 metres to 305.0 metres. True thicknesses of mineralized intercepts can be approximated from cross sections of previously announced drill holes in associated areas. The most significant assay results are shown in the following tables;
Main Mineralized Trend (Ag, Au, Cu)
Investorideas.com Newswire
* Silver equivalency includes silver, gold and copper and excludes lead, zinc, molybdenum, tin and tungsten values. Ag:Au is 50:1, Ag:Cu is 86:1, based on 5 year historic metal price trends of US$24/oz silver, US$1200/oz gold, US$3/lb copper. 100% metallurgical recovery is assumed. All numbers are rounded.
Intervals are sampled or drilled widths. True thicknesses of mineralized intercepts can be approximated from cross sections of previously announced drill holes in associated areas
All sample analyses presented in this news release were completed by ALS Chemex in Zacatecas, Mexico and North Vancouver, BC, Canada.
Mineralized Trend Surface Sampling
Continuous surface channel sampling along newly cut access roads has helped define the potential of near-surface higher grade Ag-Au-Cu mineralization in the central and southern areas of the Trend. Results represent new surface exposures of both manto and structure/stockwork related mineralization with up to 99 metres grading 116.8 gpt Ag, 0.32 gpt Au, 0.63% Cu or 187.6 gpt Ag Eq.
Investorideas.com Newswire
* Silver equivalency includes silver, gold and copper and excludes lead, zinc, molybdenum, tin and tungsten values. Ag:Au is 50:1, Ag:Cu is 86:1, based on 5 year historic metal price trends of US$24/oz silver, US$1200/oz gold, US$3/lb copper. 100% metallurgical recovery is assumed. All numbers are rounded.
Intervals are sampled or drilled widths. True thicknesses of mineralized intercepts can be approximated from cross sections of previously announced drill holes in associated areas.
Contact Zone (W, Cu, Au) and Santo Nino Target (massive sulphides, W, Cu)
Eight holes were drilled on the near-surface portion of the Contact Zone which is located within the Trend boundaries but is a separate target from the manto and structure mineralization. The Trend mineralization is located geologically and vertically above the Contact Zone. The Contact Zone mineralization consists of skarning with stockwork veining and occurs adjacent to intrusive stock and dykes which are exposed at surface in the southwestern portion of the Trend. Copper and gold values appear to be higher on the eastern edge of the Contact Zone compared to the western edge. Contact Zone holes also contain anomalous Pb, Zn, Mo and Sn.
Partial drilling of the Contact Zone shows consistent intercepts of wide-spread tungsten (W03), gold (Au), copper (Cu) mineralization from surface to depth (up to approximately 300 metres vertical). All drilling to date that has intercepted intrusive(s) has also intercepted the Contact Zone over an area of approximately 2.5 kilometres by 1.2 kilometre with estimated thicknesses ranging from 10 to 200 metres. The Contact Zone is considered a "potential large bulk tonnage tungsten target" which will be presented in the next resource estimation due in Q4 2012. Continuous channel sampling along new access roads shows tungsten mineralization up to 305 metres grading 0.063% W03 with anomalous grades of Au, Cu, Ag (see Table below and attached Figure).
Hole L J DD12-74 was drilled on the Santo Nino Target approximately 1 kilometre east of the Trend and intercepted 35.2 metres of massive and semi-massive sulphides grading 52.2 gpt Ag, 0.05 gpt Au and 1.6% Cu with 0.037% W03. This is considered a new discovery at La Joya. Further drilling is planned to determine the dimensions of this mineralization.
Contact Zone and Santo Nino Target (W, Cu, Au)
Investorideas.com Newswire
* Silver equivalency includes silver, gold and copper and excludes lead, zinc, molybdenum, tin and tungsten values. Ag:Au is 50:1, Ag:Cu is 86:1, based on 5 year historic metal price trends of US$24/oz silver, US$1200/oz gold, US$3/lb copper. 100% metallurgical recovery is assumed. All numbers are rounded.
Intervals are sampled or drilled widths. True thicknesses of mineralized intercepts can be approximated from cross sections of previously announced drill holes in associated areas.
Near surface tungsten/molybdenum mineralization encountered in both the Contact Zone and at the adjacent Coloradito target have grades similar to current economic or potentially economic near surface bulk tonnage deposits such as Thompson Creek Mine, ID (0.046 to 0.081 % Mo), Endako, BC (0.030 to 0.046 % Mo) Sisson, NB (0.031% Mo, 0.094% WO3), and El Creston, Mexico (0.071% Mo, 0.06% Cu). All references are from public company websites. Tungsten mineralization at the Coloradito target is up to 116 metres thick grading 0.048% Mo to 0.098% WO3.
Hole L J DD12-67 and L J DD12-69 encountered only intrusive and showed no significant mineralization.
The Phase II drill program is designed to test approximately 2.5 kilometres of the Trend which includes at least 8 near-vertical structures/stockwork zones, 14 near-horizontal, stacked mantos plus the Contact Zone which is adjacent to the underlying intrusive. Drilling on the southern extension of the Trend and Contact Zone continues with three core drill rigs. A reverse circulation drill is expected to be added in October 2012. Based on Company surface mapping, sampling and historic drill hole results, the southern area is thought to be potentially the highest grade area along the Trend. The Company is currently examining the potential for a near-surface, higher grade, low strip open pit as a conceptual "starter pit" that will be evaluated in an upcoming Preliminary Economic Assessment.
Core samples for holes L J DD12-75 to L J DD12-90 are currently being logged, sampled or are in the laboratory for analysis. The Company is currently drilling hole L JDD12-93 located on the southern part of the Trend. Assays for the next series of holes will be reported upon receipt and compilation. Several holes contain anomalous molybdenum, tungsten, tin, lead and zinc values over significant widths in the skarn. The significance of these associated mineral zones is being examined with partial near-surface tungsten results presented in the Table above.
The La Joya Deposit (Mineral Mineralized Trend) currently has estimated Inferred Resources of:
Investorideas.com Newswire
* Silver equivalency includes silver, gold and copper and excludes lead, zinc, molybdenum and tungsten values. Ag:Au is 50:1, Ag:Cu is 86:1, based on 5 year historic metal price trends of US$24/oz silver, US$1200/oz gold, US$3/lb copper. 100% metallurgical recovery is assumed.
**Classified by EBA, A Tetra Tech Company and conforms to NI 43-101, 43-101CP, and CIM definitions for resources. All numbers are rounded. Inferred Resources have been estimated from geological evidence and limited sampling and must be treated with a lower level of confidence than Measured and Indicated Resources.
*** Mineralization boundaries used in the interpretation of the geological model and resource estimates are based on cutoff grades of 15 gpt Ag Eq and 30 gpt Ag Eq using the metal price ratios described above.
Please refer to the January 4, 2012 news release and to the La Joya NI 43-101 Technical Report dated February 20, 2012 for further details of the Inferred Resource estimate.
The core drilling of the Phase II drill program is anticipated to be complete in October, 2012 with a subsequent revision and announcement of updated resources in Q4 2012. Extensive metallurgical test work is underway to examine the amenability and potential metallurgical recoveries of Ag, Au, Cu, W, Mo, Sn, Zn and Pb. Test work results will be presented in the next NI 43-101 Technical Report.
The current NI43-101 resource estimate for La Joya is 101.9 million ounces of silver equivalent as set out in the table above. Based on the current geologic model, drilling and sampling from the Phase I & II programs it is reasonable that the recently discovered mineralized systems could potentially result in a 50 to 100% increase in current inferred mineral resources. This potential increase in resources is conceptual in nature and insufficient exploration has been completed to define the additional mineral resource. It is uncertain that further exploration will result in the recently discovered mineralized systems being delineated as a new mineral resource.
The Qualified Person under National Instrument (NI 43-101) Standards of Disclosure for Mineral Projects for this News Release is N. Eric Fier, CPG, P.Eng, and Chief Operating Officer for SilverCrest Mines Inc., who has reviewed and approved its contents.
SilverCrest Mines Inc. (TSX-V: SVL; NYSE MKT: SVLC) is a Mexican precious metals producer with headquarters based in Vancouver, BC. SilverCrest’s flagship property is the 100%-owned Santa Elena Mine, which is located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, México. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango State.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
Disclaimer: Investorideas.com does not make stock recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Silvercrest Mines has compensated Investorideas for annual news publication and distribution and company profile: nine thousand seven hundred starting August 2012
More info: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

China Stock News Alert: China Nuokang Bio-Pharmaceutical (NASDAQ: NKBP) Gains on Going Private Deal

New York, New York - September 27, 2012 (Investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors issues a trading alert for China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP), one of the top gainers on NASDAQ in morning trading. The stock is trading at $5.2692, gaining 0.4892 or 10.23% as of 11:34AM EDT.

The Company announced today that it has entered into an Agreement and Plan of Merger with Kingbird Investment Inc. ("Parent"), a Cayman Islands exempted company with limited liability and beneficially owned by Ms. Yuhuan Zhu, the wife of Mr. Baizhong Xue, the Company's Chairman and Chief Executive Officer, and Kingbird Mergerco. Inc., a Cayman Islands exempted company with limited liability and a direct wholly-owned subsidiary of Parent ("Merger Sub").
This is one of many China companies that has announced a going private deal in the past year.
Investorideas.com Newswire China Nuokang Bio-Pharmaceutical Inc. (NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 4,200 hospitals in China. Nuokang's principal products include Baquting(R), China's leading hemocoagulase product by market share, Kaitong(R), a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant product that addresses diabetic neuropathy. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. www.nkbp.com
About NASDAQ
http://www.nasdaq.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/ Resources/Newsletter.asp
Become an Investorideas.com Member and access our 13 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Wednesday, September 26, 2012

Investorideas.com Launches "Share of the Universe", the Only Share Certificate to Never Lose Value

New York, New York - September 26, 2012 (www.investorideas.com newswire) Investorideas.com, an investor research portal specializing in sector for independent investors launches , Shares of the Universe, a new concept in giving and giving back to the Universe.
The idea, based on the stock market with shares going up and down, is to create and give a share certificate that can never lose value.
Each share of the universe certifies that the recipient is entitled to one share of the Universe and is entitle to all the rights and privileges if offers. Unlike publicly traded companies, there are an unlimited number of shares available.
Each certificate is in PDF format and can be emailed or printed and framed. Full size is 11.69 x 8.27 inches. Shares can be purchased by Paypal for $9.97 with $2.00 of each purchase to be donated back to charity or non- profit of choice.
Learn more: http://www.investorideas.com/Share-of-the-Universe.asp
Investorideas.com - Share of the Universe About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Gains

New York, New York - September 26, 2012 (Investorideas.com Newswire, www.biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks issues a trading alert for Sunshine Biopharma Inc. (OTCBB: SBFM) . The stock is trading at $ 0.31, up 0.03 or 10.71% as of 1:42PM EDT on over 86,000 shares, with a day high of $0.34.
The Company reported news yesterday that that its paper on Adva-27a preclinical research results has been accepted and will be published in the October issue of ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment.
Full news: http://www.investorideas.com/CO/SBFM/news/2012/09251.asp
Investorideas.com Newswire About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.

www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces the Appointment of Dr. Stephen Z. Fadem to its Extracorporeal Science Advisory Board

SAN DIEGO - September 26, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), announced today that Dr. Stephen Z. Fadem has agreed to join the company's Extracorporeal Science Advisory Board. Dr. Fadem is active as a practicing Houston nephrologist, teacher, lecturer and researcher. He began practice in 1978 after completing a renal fellowship at The University of Texas Health Science Center in San Antonio. He is a graduate of the University of Oklahoma College of Medicine, and did his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston. He is a Clinical Professor of Medicine, Baylor College of Medicine.
Investorideas.com Newswire
Dr. Fadem is also a Fellow of the American College of Physicians, Fellow of the American Society of Nephrology and diplomate of the American Board of Quality Assurance and Utilization Review Physicians. He has served as the Chairman of the (National Kidney Foundation (NKF) of Southeast Texas Medical Advisory Board, and has received their Lifetime Achievement Award and the Myron L. Jenkins Award.
On a national level, Dr. Fadem is co-chairman of the Medical Advisory Board of the American Association of Kidney Patients (AAKP), and a past vice-president of the AAKP Board of Directors. He has also served on the Board of Directors of the Renal Physicians Association, and actively serves on two national RPA committees, the Government Affairs Committee and the Health Finance Committee. Dr. Fadem has been active in the Forum of ESRD Networks, was a member of the CMS Clinical Performance Measures Committee. He serves as a consultant to the computer industry in the development of CKD management software and is the founder of Touchcalc, a software design company. He lectures frequently on dialysis management, preventive nephrology, vascular calcification, anemia, patient education, CKD education, and computer technology and computer security. Dr. Fadem is the co-editor of AAKP Renalife, and is a reviewer for several peer-reviewed journals.
Dr. Fadem has been nationally recognized, receiving the AAKP Nova Award, the NKF Distinguished Service Award. He has also received the NKF Presidents Award. He has been awarded the Peter Lundin Award for his contributions to patient education and The Visionary Award for his contributions to CKD education. He has also been named as one of America's Top Doctors by Castle Connolly and US News and World Report.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

NASDAQ Morning Mover: Life Partners (NASDAQ: LPHI) Gains 95% on Ruling

New York, New York –September 26, 2012 – (www.investorideas.com newswire, ) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors issues a trading alert for Life Partners Holdings, Inc. (NASDAQ: LPHI), the top percentage gainer on NASDAQ in morning trading, currently at $2.85 , gaining 1.39 or 95.21% as of  11:00AM EDT  on over 2.9 Millions shares.

The stock moved on news that Travis County District Judge Stephen Yelenosky ruled that the life settlement transactions that it facilitates are not securities under Texas law.

Life Partners CEO, Brian Pardo, expressed gratitude for the integrity of the judicial system. “The Attorney General brought this case knowing that both a Federal Court of Appeals and a Texas appeals court have ruled specifically that Life Partners’ life settlements are not securities. The Attorney General has issued inflammatory press releases and used this suit as a vehicle to make baseless claims of fraud, insolvency and a lack of regulation. None of that is true. We have been in business for 20 years. We have facilitated over 143,000 purchaser transactions involving over 6,500 policies totaling over $3 billion in face value.”



Life Partners Holdings, Inc. (NASDAQ: LPHI) is a financial services company and the parent company of Life Partners, Inc. (“LPI”), one of the oldest and most active companies in the United States engaged in the secondary market for life insurance known generally as “life settlements.” 

About NASDAQ
http://www.nasdaq.com/

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .  
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com


Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp

Become an Investorideas.com Member and access our 14 online stock directories 24/7 – water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/


Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com



 

OTC Tech Stock Trading Alert; Mimvi (OTC: MIMV) Continues Run on Microsoft (MFST) News


New York, NY - September 26, 2012 (Investorideas.com newswire, www.techsectorstocks.com) Investorideas.com staff: Investor Ideas, www.InvestorIdeas.com, a global investor research portal for independent investors, issues a tech stock trading alert for Mimvi, Inc. (OTC: MIMV), currently trading at $0.62, up 0.05 or 8.77% as of 10:02AM EDT on over 2.3 Million shares. The stock had a morning high of $0.72.
The stock soared following news yesterday when it announced that it has finalized a partnership agreement with Microsoft Corp (NASDAQ:MFST). The partnership will see Mimvi develop a number of products and services to complement Microsoft's Windows Azure and Windows Mobile 8 Platforms. The agreement also involves Microsoft making investments in Mimvi in the form of engineering services, software, and cash.
Investorideas.com Newswire About Investorideas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get free investor news and stock alerts for tech stocks and other sectors
Sign Up: http://www.investorideas.com/ Resources/ Newsletter.asp
Join Investor Ideas Get 14 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/ membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure: MIMV is a previous expired showcase tech stock on Investorideas.com www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Tuesday, September 25, 2012

Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Gains 40% on News

New York, NY - September 25, 2012 (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID) trading up over 40% following news today.
The Company reported an update to its stockholders on its pursuit of BioWatch Generation 3, Phase II. Two weeks ago, the Department of Homeland Security ("DHS") revised its procurement strategy for BioWatch Generation 3, Phase II, which now will consist of a two-stage procurement which includes two to three years of testing estimated at $89 million. A draft request for proposal ("RFP") on this effort is scheduled for release in the fourth quarter of calendar 2012. PositiveID's patented M-BAND biodetector was developed under a competitive award from the DHS Science & Technology Directorate ("S&T").
Investorideas.com Newswire About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/ today/ investorideas.com
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com:
Contact: 800 665 0411

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) To Present at the Exosomes and Microvesicles 2012 Conference

SAN DIEGO - September 25, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), disclosed today that its Chairman and CEO, Jim Joyce will present at the Exosomes and Microvesicles 2012 conference, which is being hosted by The American Society for Exosomes and Microvesicles. The event will be held at the Wyndham Lake Buena Vista Resort in Orlando, Florida and runs from September 29th through October 2nd. Mr. Joyce's presentation is scheduled for 10:10 a.m. on October 2nd and is entitled: Extracorporeal clearance of tumor-secreted exosomes as an adjunct to enhance cancer therapy efficacy. Additional information on the event can be found online at www.exosomesandmicrovesicles.org.
Investorideas.com Newswire
The Aethlon Medical presentation will review the attributes of the Aethlon Hemopurifier® as an adjunct medical device that can be combined with chemo and immunotherapies as a strategy to improve cancer treatment outcomes. The Hemopurifier®, which is a first-in-class device being advanced in Hepatitis C (HCV) care, has also demonstrated the ability to capture cancer-promoting exosomes secreted by tumors. Tumor-secreted exosomes have emerged to become a potentially vital therapeutic target in cancer as researchers have reported these microvesicular particles promote tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. Researchers have also reported that exosomes seed the spread of metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Homebuilder Stock Trading Alert: Home Depot (NYSE:HD) Breaks 52-Week High

New York, New York - September 25, 2012 (www.investorideas.com newswire. www.homebuilderstocknews.com) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research including homebuilder stocks issues a trading alert for The Home Depot, Inc. (NYSE :HD), currently trading at $60.15, up 0.76 or 1.29% as of 10:30AM on 1.8 Million shares. The stock broke through its 52 week high of $60.00 in this morning's trading session.
The homebuilding sector has had several stocks break through 52 week highs recently with stronger housing data coming in.
Investorideas.com Newswire The Home Depot is the world's largest home improvement specialty retailer, with 2,250 retail stores in all 50 states, the District of Columbia, Puerto Rico, U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. In fiscal 2011, The Home Depot had sales of $70.4 billion and earnings of $3.9 billion. The Company employs more than 300,000 associates. The Home Depot's stock is traded on the New York Stock Exchange (HD) and is included in the Dow Jones industrial average and Standard & Poor's 500 index.
About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including homebuilder stocks, beverage stocks, water stocks, biotech stocks and more.
Research homebuilder stocks at the Investorideas.com stock directory:
http://www.investorideas.com/Companies/HomebuilderStocks/HomebuilderStockList.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access 14 online stock directories
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock News: Sunshine Biopharma's (OTCBB: SBFM) Adva-27a Preclinical Research Results to Be Published in October Issue of ANTICANCER RESEARCH

MONTREAL - September 25, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports that its paper on Adva-27a preclinical research results has been accepted and will be published in the October issue of ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment.

Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment. The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal (Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology (http://ar.iiarjournals.org).
Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Cientifica (SIIC) Databases.
About Sunshine Biopharma Inc. (OTCBB : SBFM ):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer (www.sunshinebiopharma.com).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Contact:
For Additional Information
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Published at Investorideas.com newswire
Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Monday, September 24, 2012

Biodefense Stock Breaking News: PositiveID Corporation (OTCBB: PSID) Comments on Department of Homeland Security's Revised Procurement Strategy for BioWatch Generation 3, Phase II

DELRAY BEACH, Fla. - September 24, 2012 - (Investorideas.com Newswire) PositiveID Corporation (OTCBB: PSID) ("PositiveID" or "Company"), an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for diabetes management and rapid medical testing, today provided an update to its stockholders on its pursuit of BioWatch Generation 3, Phase II. Two weeks ago, the Department of Homeland Security ("DHS") revised its procurement strategy for BioWatch Generation 3, Phase II, which now will consist of a two-stage procurement which includes two to three years of testing estimated at $89 million. A draft request for proposal ("RFP") on this effort is scheduled for release in the fourth quarter of calendar 2012. PositiveID's patented M-BAND biodetector was developed under a competitive award from the DHS Science & Technology Directorate ("S&T").

The purpose of BioWatch Generation 3, Phase II is to obtain a fully autonomous networked biodetection capability that will be deployed, operated, and sustained, both indoor and outdoor, in selected U.S. BioWatch jurisdictions to continuously monitor the air for agents of biological concern. The original procurement outlined in the draft solicitation released by DHS in August 2011, with an estimated contract value of $3.1 billion, contemplated a single procurement resulting in a single award Indefinite Delivery Indefinite Quantity (IDIQ) contract for Performance Testing, Low Rate Initial Production (LRIP), Operational Test & Evaluation (OT&E), Detector Production, Deployment, Sustainment and Disposal.
The revised strategy, released by DHS two weeks ago, would consist of a two-stage procurement using a competitive down-selection between stages. Stage 1 would be for Performance Testing of candidate systems and may result in the award of multiple contracts depending on the technical merits of proposals submitted and the availability of funding. Stage 2 would be a separate competition and result in the award of a single contract for LRIP, OT&E, Full Rate Production, Deployment, Sustainment and Disposal. To be considered for the Stage 2 award, a company would need to demonstrate a design maturity and data set equivalent to that of Stage 1 participants.
William J. Caragol, Chairman and CEO of PositiveID, stated, "We believe the revised strategy for BioWatch, allowing for performance testing of qualifying systems in preparation for the full roll-out of the $3.1 billion procurement, provides us an opportunity to prove our M-BAND system, the only system of its kind that was demonstrated previously in the field under the DHS S&T BAND Program. Additionally, we continue to have discussions with potential strategic partners to prepare the Company for success in BioWatch Gen-3, Phase II."
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that it has made significant progress realigning its business with a focus on its molecular diagnostics platform; the likelihood that the Company also continues to make strong progress in the diabetes management segment of its business; the likelihood that the Company will enter into strategic partnerships and/or teaming agreements with large government contractors for M-BAND manufacturing and system integration for BioWatch Gen-3; the likelihood that the Company will submit a proposal upon release of the final BioWatch Gen 3 RFP, currently scheduled for release in the fourth quarter of calendar 2012, from Department of Homeland Security for the $3.1 billion BioWatch Gen-3 procurement; the likelihood that the Company will commence the second stage of Easy Check clinical study at Schneider Children's Medical Center in Israel; the likelihood that the Company will complete a bench-top unit of the GlucoChip glucose-sensor and initiate strategic partnerships; the likelihood that the Company will continue development of its Dragonfly Rapid MDx Cartridge-based diagnostic system for point-of-care diagnostics; the likelihood that the Company will complete the license and/or sale of the VeriChip and iglucose product lines to position them with the best partners for market exploitation and monetization; the likelihood that the Company will complete a strategic financing to capitalize the Company to execute on these opportunities; the likelihood that significant opportunities that lie ahead, including BioWatch Gen 3 and the continued development of the Company's innovative Dragonfly system; the likelihood that the Company will continue to execute its plan, described above; the likelihood that the Company is well positioned to capitalize on the BioWatch Gen 3 opportunity and to make meaningful steps in the commercialization of our diabetes management products; the likelihood that that progress, in conjunction with a strategic financing to fully capitalize the Company, will allow the Company to unlock value for stockholders; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize its M-BAND system and Dragonfly system, as well as its diabetes management products; the Company's ability to complete the license and/or sale of the VeriChip and iglucose product lines to position them with the best partners for market exploitation and monetization; the Company's ability to attract strategic partners; the Company's ability to complete a strategic financing; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, and 10-Qs filed on August 20, 2012, May 14, 2012, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

OTCBB Mid-Day Movers; ATTD, MFTH, FRCN, APDN

New York, New York - September 24, 2012 (Investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors reports on the top ten volume traders on the OTCBB for mid day trading
Attitude Drinks Inc (OTCBB: ATTD) is last at $0005, down -0.0003 or 37.50% on volume of 48.56 Million shares.
Medisafe 1 Technologies Corp. (OTCBB: MFTH) is trading at $ 0.0058, up 0.0001 or 1.75% on 21.48 Million.
Firemans Contractors Inc. (OTCBB: FRCN) is last at $0.0034, up 0.0016 or 88.89% on 18.87 Million shares changing hands.
Investorideas.com Newswire Applied DNA Sciences Inc. (OTCBB: APDN) is trading up at $ 0.264. Gaining 0.0445 or 20.27% on volume of 10.48 Million.
Amarantus Biosciences Inc. (OTCBB: AMBS) is trading at $ 0.01, up 0.0049 or 96.08% on 5 7.61 Million

Advanced Cell Technology Inc. (OTCBB: ACTC) is down, trading at $0.0773, the negative -0.0027 or 3.38% on 5.18 Million shares.
Active Health Foods Inc. (OTCBB: AHFD) is trading at $ 0.0028, down -0.0002 or 6.67% on 3.37 Million shares.
Digerati Technologies Inc. (OTCBB: DTGI) is trading at $ 0.004, down -0.0002 or 4.76 on volume of 3.08 Million.
AccelPath Inc. (OTCBB: ACLP) is trading up at $ 0.017, gaining 0.01 or 142.86% on 2.87 Million shares.
Internal Fixation Systems Inc. (OTCBB: IFIX) is trading at $0.0024, up 0.0002 or 9.09%on 2.55 Million shares.
About OTCBB:
http://www.otcbb.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 13 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Homebuilder Stocks Breaking News: Lennar (NYSE:LEN) Reports Third Quarter EPS of $0.40

New York, New York - September 24, 2012 (Investorideas.com newswire, www.homebuilderstocks.com) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research including homebuilder stocks issues an investor alert for Lennar Corporation (NYSE:LEN and LEN.B), reporting third quarter earnings . The stock traded as high as $38.27 following the earnings news but has pulled back with the general markets. The stock is now trading at $36.71, down 0.80(2.13%) 10:41AM EDT on over 5.7 Million shares volume.

Earnings Summary -
  • Net earnings of $87.1 million, or $0.40 per diluted share, compared to net earnings of $20.7 million, or $0.11 per diluted share
  • Deliveries of 3,655 homes - up 28%
  • New orders of 4,198 homes - up 44%; cancellation rate of 17%
  • Backlog of 4,513 homes - up 79%; backlog dollar value of $1.3 billion - up 95%
  • Revenues of $1.1 billion - up 34%
  • Gross margin on home sales of 23.2% - improved 210 basis points
  • S, G&A expenses as a % of revenues from home sales of 12.0% - improved 230 basis points
  • Operating margin on home sales of 11.2% - improved 440 basis points
  • Lennar Homebuilding operating earnings of $71.3 million, compared to $27.1 million
  • Lennar Financial Services operating earnings of $25.3 million, compared to $8.0 million
  • Rialto Investments operating earnings totaled $7.7 million (including $13.4 million of net loss attributable to noncontrolling interests), compared to $5.7 million (net of $6.1 million of net earnings attributable to noncontrolling interests)
  • Lennar Homebuilding cash and cash equivalents of $692.0 million
  • Issued $400 million of 4.75% senior notes due 2017
  • Completed the repurchase of $204.7 million aggregate principal amount of 5.95% senior notes due 2013 through a tender offer, resulting in a $6.5 million pre-tax loss
  • No outstanding borrowings under the $525 million credit facility
  • Lennar Homebuilding debt to total capital, net of cash and cash equivalents, of 47.7%
Investorideas.com Newswire Lennar Corporation, founded in 1954, is one of the nation's leading builders of quality homes for all generations. The Company builds affordable, move-up and retirement homes primarily under the Lennar brand name. Lennar's Financial Services segment provides mortgage financing, title insurance and closing services for both buyers of the Company's homes and others. Lennar's Rialto Investments segment is focused on distressed real estate asset investments, asset management and workout strategies. Previous press releases and further information about the Company may be obtained at the "Investor Relations" section of the Company's website, www.lennar.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including homebuilder stocks, beverage stocks, water stocks, biotech stocks and more.
Research homebuilder stocks at the Investorideas.com stock directory:
http://www.investorideas.com/Companies/ HomebuilderStocks/ HomebuilderStockList.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/ investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/ Resources/Newsletter.asp
Become an Investorideas.com Member and access 14 online stock directories
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Friday, September 21, 2012

TSX Top Trader: Gold Stock CGA Mining (TSX:CGA) (ASX:CGX)

New York, New York - September 21, 2012 (Investorideas.com Mining stocks newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors reports on the top volume trader for Friday’s session. CGA Mining Limited (TSX:CGA.TO) (ASX:CGX) leads , trading at $2.99, gaining 0.20 or 7.17% as of 1:31PM EDT on over 14.6 Million shares. The stock had a high of $3.03.
Investorideas.com Newswire CGA is listed on the main board of the Toronto Stock Exchange and ASX. The Masbate Gold Project in the Philippines was successfully constructed with first gold poured mid-2009. The project has a total measured and indicated resource base of 5.13M ounces of gold, total inferred resource base of 2.83M ounces of gold and a proven and probable reserve of 3.097M ounces of gold.
About TSX

http://www.tmx.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts including TSX alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com